Enlivex (ENLV) Beginning Cash Balance (2016 - 2025)
Enlivex (ENLV) posted quarterly Beginning Cash Balance of $3.7 million for Q1 2025, up 204.32% year-over-year from $1.2 million in Q1 2024, and up 204.32% quarter-over-quarter from $1.2 million in Q1 2024.
Enlivex (ENLV) Beginning Cash Balance (2016 - 2025) Analysis & Trends
Enlivex's Beginning Cash Balance history runs 10 years deep, the most recent figure standing at $3.7 million for Q1 2025.
- In Q1 2025, Beginning Cash Balance rose 204.32% year-over-year to $3.7 million; the TTM figure through Sep 2025 stood at $3.7 million (up 204.32% YoY), while the FY2017 annual figure was $3.0 million, up 1052.67% from the prior year.
- Beginning Cash Balance for Q1 2025 stood at $3.7 million, up from $1.2 million in the prior quarter.
- The five-year high for Beginning Cash Balance was $50.4 million in Q1 2023, with the low at $1.2 million in Q1 2024.
- The 5-year median for Beginning Cash Balance is $7.0 million (2021), against an average of $14.8 million.
- The sharpest annual moves came in 2023 and 2024: Beginning Cash Balance surged 332.77% in 2023, then tumbled 97.57% in 2024.
- Enlivex's Beginning Cash Balance stood at $7.0 million in 2021, then surged by 65.94% to $11.6 million in 2022, then soared by 332.77% to $50.4 million in 2023, then sank by 97.57% to $1.2 million in 2024, then surged by 204.32% to $3.7 million in 2025.
- Business Quant data shows ENLV's Beginning Cash Balance at $3.7 million in Q1 2025, $1.2 million in Q1 2024, and $50.4 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.73 Mn |
| Sep 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Mar 31, 2023 | 50.36 Mn |
| Mar 31, 2023 | 50.36 Mn |
| Mar 31, 2022 | 11.64 Mn |
| Mar 31, 2022 | 11.64 Mn |
| Mar 31, 2021 | 7.01 Mn |
| Mar 31, 2021 | 7.01 Mn |
| Mar 31, 2020 | 5.52 Mn |
| Mar 31, 2020 | 5.52 Mn |
| Mar 31, 2019 | 9.79 Mn |
| Mar 31, 2019 | 9.79 Mn |
| Mar 31, 2018 | 9.01 Mn |
| Mar 31, 2018 | 9.01 Mn |